公开(公告)号：EP1025847A4

公开(公告)日：2003-01-08

申请号：EP98940584

申请日：1998-08-26

申请人： MITSUBISHI PHARMA CORP ,  NISSAN CHEMICAL IND LTD

发明人： EGI YASUHIRO ,  KIDO HIDEAKI ,  HAYASHI KAZUTAKA ,  KUBO YOSHIJI ,  NAKAMURA NORIFUMI

IPC分类号： C07D401/12 ,  A61K31/50 ,  A61P9/00

CPC分类号： C07D401/12

摘要： Neovascularization promoters and neovascularization potentiators, containing as the active ingredient pyridazinone compounds represented by general formula (I) or pharmacologically acceptable salts thereof wherein each symbol is as defined in the specification. The pyridazinone compounds of formula (I) and pharmacologically acceptable salts thereof have the effects of promoting neovascularization and potentiating the drugs having these effects, which makes them useful as neovascularization promoters and neovascularization potentiators.

公开(公告)号：EP1157694A4

公开(公告)日：2002-08-28

申请号：EP99973258

申请日：1999-11-30

申请人： NISSAN CHEMICAL IND LTD ,  MITSUBISHI PHARMA CORP

发明人： TANIKAWA KEIZO ,  TSURUZOE NOBUTOMO ,  SHUDO NORIMASA ,  YAMASHITA TORU ,  ISHIWATA NORIHISA ,  KIDO HIDEAKI ,  EBISU HAJIME ,  HAYASHI KAZUTAKA ,  KUBO YOSHIJI ,  NAKAMURA NORIFUMI

IPC分类号： A61K31/50 ,  A61K31/501 ,  A61P15/10

CPC分类号： A61K31/501 ,  A61K31/50

摘要： An erectile dysfunction remedy which comprises as the active ingredient a 3(2H)-pyridazinone derivative represented by formula (I) or a pharmacologically acceptable salt thereof, wherein the symbols each is the same as defined in the description.

公开(公告)号：EP1146337A4

公开(公告)日：2002-04-17

申请号：EP99973328

申请日：1999-12-02

申请人： MITSUBISHI PHARMA CORP

发明人： KAWAMURA TOORU ,  HORIE SATOSHI ,  AKIRA TOSHIAKI ,  NAKAMURA NORIFUMI ,  MARUYAMA TOMOYUKI ,  HAYASHI KAZUTAKA

IPC分类号： A61K31/00 ,  G01N33/50 ,  G01N33/88 ,  A61K31/557 ,  A61K31/70 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  C12N15/10 ,  G01N33/15

CPC分类号： G01N33/5011 ,  A61K31/00 ,  G01N33/5008 ,  G01N33/5058 ,  G01N33/88 ,  G01N2500/00 ,  G01N2500/10 ,  G01N2510/00

摘要： A method for screening an apoptosis inhibitor characterized by screening a candidate via an effect on PGT. A cell protecting agent containing as the active ingredient a substance which can be incorporated into cells via prostaglandin transporter (PGT); and a screening method therefor comprising measuring the uptake into cells via PGT. An apoptosis inducer containing as the active ingredient a substance having a PGT inhibitory effect; and a screening method therefor comprising measuring the ability to induce apoptosis of cells with the expression of PGT. Because of having a cell apoptosis inhibitory effect, the cell protecting agent is useful as a nerve cell apoptosis inhibitor, a nerve cell protecting agent, etc. and applicable to the prevention or treatment of nervous diseases, etc. The apoptosis inducer is useful in preventing and/or treating diseases in association with cell proliferation such as tumor, etc.

公开(公告)号：EP1008349A4

公开(公告)日：2004-01-14

申请号：EP98938967

申请日：1998-08-24

申请人： MITSUBISHI PHARMA CORP ,  LTT BIO PHARMA CO LTD

发明人： EGI YASUHIRO ,  KUBO YOSHIJI ,  INOUE SATORU ,  KIDO HIDEAKI ,  NISHIKAWA MASAKUNI ,  HAYASHI KAZUTAKA

IPC分类号： A61K31/557 ,  A61K31/5575 ,  A61K38/18 ,  A61K45/06

CPC分类号： A61K31/727 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/70 ,  A61K31/715 ,  A61K38/1825 ,  A61K45/06 ,  A61K31/505 ,  A61K2300/00

摘要： An angiogenesis promoter containing a compound of the following formula (I) wherein R is acyl, R is alkyl, R and R are the same or different and each is hydrogen atom or hydroxy protecting group and R is alkyl, as an active ingredient. This compound itself not only has an angiogenesis promoting effect but also potentiates the angiogenic effect by a drug (e.g., b-FGF) having such effect. Therefore, it can express the angiogenesis promoting effect more effectively in the ischemic tissues and the site under different disease state, where b-FGF has locally increased.